Skip to main content
Partnership to advance mRNA cancer vaccine development for 5 targets
10/19/2017

German company CureVac and Eli Lilly and Co. will collaborate on developing up to five mRNA cancer vaccines using CureVac's RNActive technology, with Lilly determining the diseases to be targeted, conducting clinical studies and marketing any FDA-approved vaccines. Lilly will pay CureVac $50 million in cash upfront plus up to $1.7 billion in milestones and will also invest about $53.1 million in the company, granting Lilly an approximate 3% share in the biotech firm.

Full Story: